Clinical trials located in

Brindisi

Brindisi city is located in Italy. Currently, 6 clinical trials are being conducted in this city.

Brindisi, a historic port city in Italy’s Apulia region, boasts a rich history dating back to ancient times. Known for its natural harbor, the city served as a crucial gateway to the East during the Roman era. The iconic Roman Columns, marking the end of the ancient Via Appia, stand as a testament to Brindisi’s historical significance. The city’s strategic location has made it a focal point throughout history, from the Crusades to World War II. Today, Brindisi blends its ancient past with modern vitality, hosting a vibrant waterfront and a plethora of archaeological treasures.

  • CT-EU-00068198

    Study of alpelisib and fulvestrant for advanced breast cancer treatment

    This trial is looking at the effects of the combined use of two drugs, alpelisib and fulvestrant, in treating patients who have advanced breast cancer. The cancer should be HR-positive and HER2-negative, and have a specific mutation (PIK3CA). If the patients already underwent certain other treatments like CDK4/6 Inhibitors and aromatase Inhibitors, but the cancer has progressed, they could join this trial. Doctors will be able to compare the results of patients taking alpelisib and fulvestrant together, with those taking fulvestrant with a placebo, They aim to check which combination works better in delaying the advance of cancer or in improving a patient’s life duration.

    • Alpelisib
    • Fulvestrant
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Comparing camizestrant with standard therapy in early breast cancer treatment

    This study, known as CAMBRIA-2, aims to test a medication called Camizestrant for treating early-stage breast cancer that is ER+ and HER2-. It will compare Camizestrant with the standard treatments currently used, which are either Aromatase Inhibitor or Tamoxifen. The study is specifically focused on patients with ER+/HER2- breast cancer who are at high or medium-high risk of their cancer returning. Before they can participate, these patients must have finished all planned cancer treatments, such as surgery or chemotherapy, and currently show no signs of the disease. The main goal of the study is to see whether Camizestrant helps to prevent breast cancer from coming back. This would be measured by looking at the time from when patients join the study to when they first see their breast cancer return, or unfortunately, pass away. The study also aims to see whether Camizestrant improves other measures, such as overall survival and quality of life.

    • camizestrant
    • Abemaciclib
    • Anastrozole
    • Letrozole
    • Exemestane
    • tamoxifen
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Italy:

.